FY2026 EPS Estimate for Aethlon Medical Decreased by Analyst

Aethlon Medical, Inc. (NASDAQ:AEMD) – Research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Aethlon Medical in a report issued on Tuesday, February 17th. HC Wainwright analyst S. Ramakanth now expects that the medical equipment provider will post earnings of ($9.49) per share for the year, down from their previous estimate of ($9.00). The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at ($0.61) EPS and FY2030 earnings at ($0.30) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Aethlon Medical currently has an average rating of “Reduce” and an average target price of $560.00.

Aethlon Medical Price Performance

Shares of AEMD opened at $2.04 on Thursday. The company has a market capitalization of $2.69 million, a PE ratio of -0.09 and a beta of 1.60. The company’s fifty day moving average price is $2.59 and its 200 day moving average price is $5.99. Aethlon Medical has a one year low of $1.86 and a one year high of $49.92.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Thursday, February 12th. The medical equipment provider reported ($2.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.44).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent filing with the SEC. 1.99% of the stock is owned by institutional investors.

Trending Headlines about Aethlon Medical

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: HC Wainwright raised 2027–2030 EPS forecasts materially versus prior, trimming expected losses in FY2027–FY2030 and lifting quarterly 2027 estimates — this signals a more constructive medium-term earnings outlook that could support the stock if execution follows through.
• Positive Sentiment: Company update on advancing an oncology trial and efforts to simplify/broaden the device application could be a clinical/program milestone with commercial implications if progress continues. AEMD: Advancing Oncology Trial
• Neutral Sentiment: An investor/shareholder call transcript was posted (prepared remarks), providing more detail for investors; the transcript itself is informational and may only move the stock if it contains unexpected news. Shareholder/Analyst Call Transcript
• Neutral Sentiment: Short-interest reports show “0” shares and a days-to-cover of 0.0 — this looks like a data/filing artifact rather than a meaningful change in positioning; therefore it’s unlikely to be a real market mover.
• Negative Sentiment: HC Wainwright cut FY2026 and Q4‑2026 estimates substantially (Q4‑2026 revised down sharply from prior), indicating near-term results may be weaker than earlier expected; that raises short-term execution and cash-burn concerns that can pressure the stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.